Recalled Medicines & supplements – Current GIS Alerts 2026
Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Sulfarinol
An out-of-specification result was obtained in stability testing for batch 020618 concerning the parameter “naphazoline nitrate contamination – other single impurity”, with the possibility that this quality defect may occur in other batches still on the market. Potential effects: nasal mucosa irritation, adverse reactions or reduced treatment effectiveness.
Cisatracurium Noridem
The tested sample of the medicinal product does not meet the requirements specified in the documentation for active substance content and product appearance, which creates a potential risk to patients' health or life. Potential effects: lack of treatment efficacy, complications during anaesthesia, life-threatening risk.
Megalia
Failure to meet quality requirements for the batch regarding microbiological purity, which poses a potential risk to patients’ health or life and was the basis for granting the decision immediate enforceability. Potential effects: infection, complications, lack of treatment safety.
Montelukast Bluefish
A discrepancy was found between the outer packaging and the Summary of Product Characteristics – a product intended for children aged 6–14 years was labelled as for children 2–5 years, which poses a threat to public health. Potential effects: improper use in children, risk of lack of efficacy or adverse effects.
Ebetrexat
It was found that the sample did not meet the product specification requirements for purity; the out-of-specification result concerned the parameter "content of related substance impurities". Potential effects: altered drug effect, possible increased adverse reactions or complications of therapy.
Clopidogrel Genoptim
The previously identified quality defect was the placement of an incorrect active substance name on the unit packaging of the medicinal product Clopidogrel Genoptim. Potential effects: incorrect use of the medicine, lack of treatment efficacy, possible treatment complications.
Gardimax Medica Spray
The advertisement of Gardimax Medica Spray and Dektac 25 mg film-coated tablets is misleading regarding their properties, suggesting they fight viruses and fever, although such indications are not included in the Summary of Product Characteristics or the patient leaflet. Potential effects: improper use of the medicine, lack of treatment efficacy, delay of appropriate therapy.
Dektac
It was found that the advertising of Gardimax Medica Spray and Dektac 25 mg film-coated tablets is misleading, attributing to them effects of “combating viruses” and “combating fever” that are not consistent with the approved Summary of Product Characteristics. Potential effects: incorrect use of the medicine, lack of treatment efficacy, possible complications.
Neosine Forte
The advertisement is misleading, suggesting that Neosine Forte tablets are effective against COVID-19 coronavirus infections, can be used in prevention and treatment of these infections, and unethically exploits fear associated with the epidemic situation. Potential effects: lack of effective treatment, delay of appropriate therapy, worsening of the disease.
Megalia
Failure to meet quality requirements for this batch was found regarding the microbiological purity parameter, which may indicate the presence of microorganisms in the product and a potential risk to patients' health. Potential effects: infections, adverse reactions, lack of treatment efficacy.
Esmya
A case of severe liver injury in a patient using ulipristal acetate 5 mg was identified, requiring liver transplantation; there is a real, significant probability of serious harm to health or life. Potential effects: severe liver damage, liver failure, life-threatening complications.
Ulipristal Acetate Gedeon Richter
The PRAC Committee recorded a new case of severe liver injury after the use of ulipristal 5 mg, which required a liver transplant; the existing risk minimisation measures were deemed insufficient. Potential effects: severe liver damage, liver failure, life-threatening condition.
Ulimyo
Severe liver injury was identified after use of the product, in one case requiring a liver transplant, indicating an unfavorable benefit-risk balance. Potential effects: severe liver damage, life‑threatening complications, lack of treatment safety.
Ulipristal Alvogen
A new case of severe liver injury requiring transplantation and a justified suspicion that the medicine causes serious adverse reactions, altering the benefit–risk balance and creating a real, high probability of risk to patients’ health or life. Potential effects: severe liver damage, life‑threatening complications.
Reseligo
A result out of specification was found for active substance content, indicating a quality defect that may lead to improper drug action. Potential effects: treatment failure or adverse reactions.
Saridon
It was found that the packaging materials do not meet requirements – some packs of the product are labeled in Hungarian, which may lead to misunderstanding of information about the medicine. Potential effects: incorrect use of the medicine, lack of efficacy, complications.
Sulfarinol
Out-of-specification results were found in tested archival samples for the listed Sulfarinol batches regarding the parameter naphazoline nitrate impurity – another single impurity. Potential effects: possible adverse reactions, lack of efficacy or other complications related to uncontrolled impurity.
Sulfarinol
Out-of-specification results were found in archival samples for the parameter naphazoline nitrate contamination – another single impurity, which creates a potential risk to patients’ health or life. Potential effects: mucosal irritation, systemic adverse effects, lack of therapeutic efficacy.
Tetmodis
Out-of-specification results were found for active substance content in batch T1702PL of Tetmodis (Tetrabenazine), which may mean an inappropriate dose for the patient. Potential effects: lack of efficacy or increased adverse effects.
Sulfarinol
Out-of-specification results were found in archival samples of Sulfarinol batches for the parameter “naphazoline nitrate contamination – other single impurity”, indicating a quality defect of the product. Potential effects: reduced treatment efficacy and possible adverse reactions of unpredictable intensity.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.